Christine Mateus

Author PubWeight™ 47.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
2 Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015 8.64
3 Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009 2.16
4 The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013 2.01
5 RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011 1.92
6 Hemophilia A induced by ipilimumab. N Engl J Med 2011 1.55
7 Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2011 1.52
8 [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]. Med Sci (Paris) 2011 1.38
9 Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 2008 1.21
10 Rituximab therapy for HIV-associated Castleman disease. Blood 2003 1.16
11 Kidney injuries related to ipilimumab. Invest New Drugs 2014 1.03
12 Vemurafenib and radiosensitization. JAMA Dermatol 2013 0.95
13 A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012 0.94
14 Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp. Am J Surg Pathol 2016 0.86
15 Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch Dermatol 2005 0.86
16 Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer Res 2013 0.84
17 Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs 2012 0.82
18 The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer 2008 0.81
19 Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status. Support Care Cancer 2011 0.79
20 [Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]. Rev Prat 2010 0.78
21 Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol 2012 0.78
22 Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations. Hum Mutat 2014 0.78
23 Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015 0.77
24 [Cutaneous effects related to the use of tyrosine kinase inhibitors]. Rev Pneumol Clin 2007 0.75
25 Scurvy in liver transplant patients. J Am Acad Dermatol 2006 0.75
26 Melanoma arising from a long-standing pigmented trichoblastoma: clinicopathologic study with complementary aCGH/mutational analysis. Am J Dermatopathol 2014 0.75
27 Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. Acta Derm Venereol 2017 0.75